Transfusion · 2003 · 73 citations · 35 references
MedicineHematologyImmunologyStem Cell TransplantationTransplant ImmunologyTransplant SurgeryDonor MatchingDonor-recipient CompatibilityHistocompatibilityPost-transplant ComplicationsTransplant ComplicationsTransplant Infectious ComplicationsNon-myeloablative ConditioningNonmyeloablative ConditioningOverall MortalityPure Red Cell AplasiaSurvival After Allogeneic TransplantationThrombotic Complications After TransplantationTransplantationTransplantation Outcome Assessment
BACKGROUND: ABO mismatch has not been thought to affect the outcome of patients undergoing myeloablative conditioning and allogeneic HPC transplantation. Data on transplant-related complications after ABO-mismatched transplantation after nonmyeloablative conditioning are limited. STUDY DESIGN AND METHODS: Therefore, 40 patients were analyzed after nonmyeloablative conditioning with regard to ABO compatibility. Eleven received a minor and bidirectional and 8 a major ABO-mismatched graft. RESULTS: Four patients had evidence of hemolysis during engraftment, being lethal in one, and three developed pure RBC aplasia. Six patients in the ABO-mismatched group developed thrombotic microangiopathy, and three of them died. ABO-identical and ABO-mismatched patients had a similar incidence of GVHD. Viral infections occurred in both groups in equal shares. Patients with an ABO-mismatch had to be rehospitalized until Day 100 for a median of 19 days versus 0 days in the identical group (p < 0.05). Overall survival was 60 and 57 percent in the ABO-identical and ABO-mismatch groups, respectively. The probability of transplant-related mortality was 0 versus 28 percent in the identical group compared to patients with an ABO mismatch (p < 0.05). The probability of relapse or progression was 76 versus 25 percent in the ABO-identical group compared to the ABO-mismatched group, respectively. CONCLUSION: Significantly more patients with ABO mismatch showed transplant-associated complications and died as a result of transplant-related causes.
35
Shimon Slavin, Arnon Nagler, E Naparstek et al. · Blood · 1998 · 1.9K citations · Full text
Medicine, Hematology, Oncology +17
Shimon Slavin, Arnon Nagler, E Naparstek et al. · Blood · 1998 · 1.8K citations
Medicine, Hematology, Oncology +17